MedTrace Logo

Treatment of Early Aggressive Rheumatoid Arthritis (TEAR)

NCT00259610 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 755

Last updated 2014-07-17

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to 1)to determine if it is better to treat all early RA patients with methotrexate in combination with hydroxychloroquine plus sulfasalazine or in combination with etanercept or reserve this treatment for patients who do not appropriately respond to methotrexate alone and 2) to determine which combination of methotrexate therapy is better

Conditions

Interventions

DRUG

methotrexate

varies

DRUG

sulfasalazine

varies

DRUG

hydroxychloroquine

varies

DRUG

etanercept

varies

Sponsors & Collaborators

  • Amgen

    collaborator INDUSTRY

  • Barr Laboratories

    collaborator INDUSTRY

  • Pfizer

    collaborator INDUSTRY

  • University of Alabama at Birmingham

    lead OTHER

Principal Investigators

  • Jeffrey Curtis, MD · University of Alabama at Birmingham

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
FACTORIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-05-31
Primary Completion
2009-06-30
Completion
2009-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00259610 on ClinicalTrials.gov